RXRX

2.4509.93%
RM

Robert M. Hershberg

Independent Director

Dr. Robert M. Hershberg, also known as Rob, M.D., Ph.D, is Director at Beckley Psytech Limited. He was a Non-Executive Director of AtaiBeckley Inc. (formerly known as Atai Beckley N.V.) (formerly known as Atai Life Sciences N.V.) since November 04, 2025 until September 11, 2026. Dr. Hershberg is Independent Director of Adaptive Biotechnologies Corporation from February 2013. Dr. Hershberg joined the Adaptive Biotechnologies Corporation in February 2013. Dr. Hershberg was Member of Scientific Advisory Board of Danaher Corporation until October 09, 2026 and serves as its Director since October 09, 2026. Dr. Hershberg was Member of Scientific Advisory Board of Danaher Corporation from April 2021 to April 2022. Dr. Hershberg is Independent Director at Recursion Pharmaceuticals, Inc. since 2026 and served as its Vice Chairman & Lead independent Director since January 01, 2026 until 2026. Dr. Hershberg was Independent Chairman of Recursion Pharmaceuticals, Inc. from June 3, 2024 until January 01, 2026. Dr. Hershberg is Independent Director of Recursion Pharmaceuticals, Inc. from March 2020. Dr. Hershberg served as Member of Scientific Advisory Board of DRAGONFLY Therapeutics, Inc. from November 2020 to June 2025. Dr. Hershberg is Member of Scientific Advisory Board of Skyhawk Therapeutics, Inc. from October 2020. Dr. Hershberg is Director of Guide Therapeutics, LLC. Dr. Hershberg is Member of Ethics Advisory Board of Variant Bio, Inc. Dr. Hershberg is Co-Founder & Executive Chairman of Cajal Neuroscience, Inc. Dr. Hershberg is Director of Eleusis Holdings Ltd from July 2021. Dr. Hershberg joined the Eleusis Holdings Ltd in July 2021. He was employed in positions of ascending responsibility at Celgene since joining in 2014, including his role as Chief Scientific Officer from January 2016 to March 2020. Dr. Hershberg is Co-Founder, President, CEO & Chairman of the Board of HilleVax, Inc. from 2024. Dr. Hershberg was President, CEO & Chairman of the Board of HilleVax, Inc. until 2024. Dr. Hershberg is Venture Partner of Frazier Life Sciences Management, LP. Dr. Hershberg is Venture Partner of Frazier Management, L.L.C. from April 2020. Dr. Hershberg joined the Frazier Management, L.L.C. in 2015. Dr. Hershberg focuses on Life Science. Dr. Hershberg was Entrepreneur-in-Residence of Frazier Management, L.L.C. Dr. Hershberg was Senior Advisor of Frazier Management, L.L.C. from 2015. Dr. Hershberg was Vice President of Corixa Corporation. Dr. Hershberg was Chief Medical Officer and Senior Vice President of Dendreon Corporation. Dr. Hershberg joined the Dendreon Corporation in January 2004. Dr. Hershberg was Executive Vice President of Business Development & Global Alliances of Celgene Corporation from April 2017 to March 2020. Dr. Hershberg was Independent Director of NS Wind Down Co., Inc. from March 2018 to April 18, 2022. Dr. Hershberg was employed at NS Wind Down Co., Inc. from March 02, 2015 to April 18, 2022. Dr. Hershberg was Independent Director of Fate Therapeutics, Inc. from May 2020 to June 7, 2024. Dr. Hershberg was employed at Fate Therapeutics, Inc. until June 7, 2024. Dr. Hershberg was Co-Founder, Chief Executive Officer, President and Director of VentiRx Pharmaceuticals, Inc. from 2012 to February 2017. Dr. Hershberg was employed at VentiRx Pharmaceuticals, Inc. from 2006 to February 2017. Dr. Hershberg was Independent Director of Silverback Therapeutics, Inc. from 2016 to November 08, 2022. Dr. Hershberg was employed at Silverback Therapeutics, Inc. until November 08, 2022. He previously served on the boards of directors of Nanostring Technologies, Inc. (Nasdaq: NSTG) from 2015 to April 2022. Dr. Hershberg was Director & Board Observer of IDEAYA Biosciences, Inc. Dr. Hershberg joined the IDEAYA Biosciences, Inc. in May 2016. Dr. Hershberg was Director of ARS Pharmaceuticals, Inc. until November 08, 2022. Dr. Hershberg was employed at ARS Pharmaceuticals, Inc. until November 08, 2022. Dr. Hershberg has Ph.D. in Biology from Salk Institute, M.D. from University of California, Los Angeles, B.S. in Molecular Biology from University of California, Los Angeles completed under the Medical Scientist Training Program (MSTP). He has been a Venture Partner at Frazier Healthcare Partners since March 2020.

Positions